TG Therapeutics, Inc. (TGTX)

NASDAQ: TGTX · USD

$57.4

+0.96 (+1.7%)· Recorded snapshot

Market cap	8.1B
Revenue (ttm)	799.5M
Net income (ttm)	441.5M
EPS (ttm)	$2.77
Shares out	141.8M
P/E (trailing)	20.7x
P/E (forward)	29.9x
Volume	705,471
Beta	1.80

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 799.5M
Net income (ttm): 441.5M
EPS (ttm): $2.77
P/E (trailing): 20.7x
P/E (forward): 29.9x
Market cap: 8.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E29.9

P25 n/aP50 n/aP75 n/a

Trailing P/E20.7

P25 n/aP50 n/aP75 n/a

ROE100.3

P25 n/aP50 n/aP75 n/a

ROIC16.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TGTX indicators

Market & fundamental data

Available fields

245

Groups with data

Currency

USD

Showing 245 of 245 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001001316
Company name	TG Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	88322Q108
Earnings date	2026-11-10
Earnings time	bmo
Employees	399
Employees change	61
Employees growth	18.05%
Enterprise value	$8.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1993
In index	RUSSELL2000
Industry	Biotechnology
IPO date	1995-12-14
Is primary listing	Yes
Is SPAC	No
ISIN number	US88322Q1085
Last 10-K release date	2026-02-27
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Last stock split date	2012-04-30
Last stock split type	Reverse
Market cap	$8.1B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$57.40
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TGTX
U.S. state	North Carolina
Website	https://www.tgtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	108.3x
Average P/E ratio (3Y)	73.83x
Earnings yield	4.82%
EV/Earnings	18.45x
EV/EBIT	59.75x
EV/EBITDA	59.7x
EV/FCF	468.55x
EV/Sales	10.19x
FCF / EV yield	0.21%
FCF yield	0.22%
Forward EV/Sales	7.36x
Forward P/E	29.88x
Forward P/S	7.18x
Graham number	16.28791
Graham upside	-70.91%
P/B ratio	13.25x
P/E ratio	20.73x
P/FCF ratio	456.92x
P/OCF ratio	444.37x
P/S ratio	9.94x
PEG ratio	1.31x
Price / tangible book value	13.15x
Price/EBITDA ratio	58.22x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	17.05%
EBITDA margin	17.07%
FCF margin	2.17%
Gross margin	82.37%
Operating margin	17.05%
Pretax margin	12.71%
Profit margin	55.22%
Profit per employee	$1.1M
Profitable quarters	9
Profitable years	3
Revenue per employee	$2M
ROA	7.28%
ROA (5Y)	-14.08%
ROCE	9.94%
ROE	100.28%
ROE (5Y)	-23.37%
ROIC	16.74%
SBC / revenue	10.15%
Tax / revenue	-42.51%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	667.52%
EPS growth (Q)	-70.59%
EPS growth (QoQ)	-58.33%
EPS growth years	4
FCF growth (Q)	427.05%
Gross profit growth	66.8%
Gross profit growth (Q)	62.95%
Gross profit growth 3Y	213.97%
Gross profit growth 5Y	214.93%
Net income growth	630.24%
Net income growth (Q)	-72.4%
Net income growth (QoQ)	-60.66%
Net income growth years	4
OCF growth (Q)	428.01%
Operating income growth	58.8%
Operating income growth (Q)	-37.8%
Revenue growth	76.08%
Revenue growth (Q)	70.27%
Revenue growth (QoQ)	17.28%
Revenue growth 10Y	135.5%
Revenue growth 3Y	221.54%
Revenue growth 5Y	219.17%
Revenue growth quarters	7
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-491,000
Depreciation and amortization	$123,000
EBIT	$136.3M
EBITDA	$136.5M
EPS	$2.77
FCF per share	$0.12
Financing cash flow	$313.7M
Free cash flow	$17.4M
Free cash flow minus SBC	$-63.8M
Gross profit	$658.6M
Income taxes	$-339.9M
Investing cash flow	$21.9M
Net borrowing	$492.7M
Net cash flow	$353.5M
Net income	$441.5M
Operating cash flow minus SBC	$-63.3M
Operating income	$136.3M
Revenue	$799.5M
Stock-based compensation	$81.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.37
Book value per share	$4.26
Debt / EBITDA	5.45
Debt / equity	1.25
Debt / FCF	43.4
Interest coverage	3.64
Long-term assets	$493.9M
Long-term liabilities	$767.1M
Net cash (debt)	$-202.2M
Net cash / market cap	-2.55%
Net debt / EBITDA	1.48
Net debt / equity	0.33
Net debt / FCF	11.63
Piotroski F-Score	4
Property, plant and equipment	$7.1M
Shareholders' equity	$604.1M
Tangible book value	$604.1M
Tangible book value per share	$4.26
Total assets	$1.6B
Total cash	$552.2M
Total debt	$754.4M
Total liabilities	$1B
WACC	13.26%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.68
Current assets	$1.1B
Current liabilities	$268.5M
Current ratio	4.27
Inventory turnover	0.93
Net working capital	$326.9M
Quick ratio	3.55
Working capital	$877.2M
Working capital turnover	1.17

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	5.56%
Dividend yield	0%
Shareholder yield	5.56%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	901.75%
10Y return CAGR	25.92%
10Y total return	901.75%
150-day SMA	$48.11
1D price change	1.7%
1M price change	-0.05%
1M total return	-0.05%
1W price change	7.9%
1W total return	7.9%
1Y price change	70.38%
1Y return CAGR	70.44%
1Y total return	70.38%
20-day SMA	$54.33
200-day SMA	$43.50
3M price change	2.96%
3M total return	2.96%
3Y price change	724.71%
3Y return CAGR	102.01%
3Y total return	724.71%
50-day SMA	$54.99
50-day SMA vs 200-day SMA	50over200
52-week high	$59.30
52-week high date	2026-07-09
52-week low	$26.76
52-week low date	2026-03-12
5Y price change	84.8%
5Y return CAGR	13.07%
5Y total return	84.8%
6M price change	62.24%
6M total return	62.24%
All-time high	$59.30
All-time high date	2026-07-09
All-time low	$1.13
All-time low date	2011-12-30
Average true range (ATR)	$2.23
Average volume	1.5M
Beta (1Y)	0.44
Beta (2Y)	0.31
Beta (5Y)	1.8
Change from 52-week high	-3.2%
Change from 52-week low	114.5%
Change from all-time high	-3.2%
Change from all-time low	5,002.22%
Change from open	2.85%
Day's gap	-1.12%
Dollar volume	$40.5M
High price	$57.40
Low price	$55.67
Monthly RSI	71.23
Open price	$55.81
Position in 52-week range	100%
Premarket change	-0.51%
Premarket close	$56.44
Premarket price	$56.15
Premarket volume	5.4K
Previous close	$56.44
Price vs 150-day SMA	19.32%
Price vs 20-day SMA	5.65%
Price vs 200-day SMA	31.96%
Price vs 50-day SMA	4.38%
Relative volume	0.48
RSI	60.22
Sharpe ratio	1.31
Sharpe ratio (3Y)	1.41
Sharpe ratio (5Y)	0.53
Sortino ratio	2.34
Sortino ratio (3Y)	2.56
Sortino ratio (5Y)	0.87
Volume	705.5K
Weekly RSI	63.57
YTD price change	92.55%
YTD total return	92.55%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	135.2M
Float percentage	95.34%
Shares change (QoQ)	-1.74%
Shares change (YoY)	-5.56%
Shares held by insiders	4.62%
Shares held by institutions	84.05%
Shares outstanding	141.8M
Short % of float	22.65%
Short % of shares	21.6%
Short ratio	16.5 days

Deeper analysis on TGTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TGTX report

Is a complete TGTX research report available?

No complete published report is available for TG Therapeutics, Inc. (TGTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TG Therapeutics, Inc. (TGTX)

Price

Financial snapshot

Fair-value bridge

Latest news · TGTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TGTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TGTX

Frequently asked questions